Trials / Sponsors / Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc.
Industry · 6 registered clinical trials — 4 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | 2025-11-03 |
| Recruiting | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | 2024-12-16 |
| Recruiting | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | 2023-11-16 |
| Recruiting | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmocicli Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 1 | 2022-08-31 |
| Active Not Recruiting | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients Breast Cancer | Phase 1 | 2021-12-10 |
| Completed | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breas Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | Phase 1 / Phase 2 | 2020-08-13 |